| Literature DB >> 35949211 |
Dana Gornick1, Anusri Kadakuntla1, Alexa Trovato1, Rebecca Stetzer2, Micheal Tadros3.
Abstract
Recent guidelines recommend that colorectal cancer (CRC) screening after age 75 be considered on an individualized basis, and discourage screening for people over 85 due to competing causes of mortality. Given the heterogeneity in the health of older individuals, and lack of data within current guidelines for personalized CRC screening approaches, there remains a need for a clearer framework to inform clinical decision-making. A revision of the current approach to CRC screening in older adults is even more compelling given the improvements in CRC treatment, post-treatment survival, and increasing life expectancy in the population. In this review, we aim to examine the personalization of CRC screening cessation based on specific factors influencing life and health expectancy such as comorbidity, frailty, and cognitive status. We will also review screening modalities and endoscopic technique for minimizing risk, the risks of screening unique to older adults, and CRC treatment outcomes in older patients, in order to provide important information to aid CRC screening decisions for this age group. This review article offers a unique approach to this topic from both the gastroenterologist and geriatrician perspective by reviewing the use of specific clinical assessment tools, and addressing technical aspects of screening colonoscopy and periprocedural management to mitigate screening-related complications. ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.Entities:
Keywords: Aged; Cancer screening; Colonoscopy; Colorectal cancer; Early detection of cancer; Elderly
Year: 2022 PMID: 35949211 PMCID: PMC9244986 DOI: 10.4251/wjgo.v14.i6.1086
Source DB: PubMed Journal: World J Gastrointest Oncol
Figure 1Practical considerations for colorectal cancer screening in older adults.
Comments on colorectal cancer screening across professional organizations
|
|
|
|
| American College of Gastroenterology (2021) | 50-75 | Screening after age 75 should be considered on an individualized basis; providers must engage in shared decision making |
| United States Preventive Services Task Force (2021) | 45-75 | Screening adults aged 76-85 should be conducted on an individualized basis; do not screen adults age 86 years and above |
| United States Multi-Society Task Force on Colorectal Cancer (2021) | 45-75 | Consider discontinuation when persons up to date with screening, who have prior negative screening reach age 75 or have < 10 yr of life expectancy. Persons without prior screening should be considered for screening up to age 85, depending on age and comorbidities. |
| Canadian Task Force on Preventive Health Care (2016) | 50-74 | Recommend not screening adults aged 75 yr and older. (Weak recommendation; low-quality evidence) |
| American College of Physicians (2019) | 50-75 | Discontinue screening in average-risk adults older than 75 yr or in adults with a life expectancy of 10 yr or less |
| American Cancer Society (2018) | 45-75 | Screening adults aged 76-85 should be conducted on an individualized basis; screening discouraged above age 85 |
Adapted from Ref. [14].
Figure 2Personalized approach to colorectal cancer screening in an older patient. Adapted from Ref. [18,19]. CCI: Charlson comorbidity index; CFS: Clinical frailty scale; PCP: Primary care provider.
Charlson comorbidity index conditions and scoring
|
|
|
|
| Age | < 50, 50-59, 60-69, 70-79, 80+ | 0, +1, +2, +3, +4 |
| Myocardial infarction | Yes/no | +1 |
| CHF | Yes/no | +1 |
| PVD | Yes/no | +1 |
| CVA or TIA | Yes/no | +1 |
| Dementia | Yes/no | +1 |
| COPD | Yes/no | +1 |
| Connective tissue disease | Yes/no | +1 |
| Peptic ulcer disease | Yes/no | +1 |
| Liver disease | None/mild/severe | +1 (mild), +3 (moderate-severe) |
| Diabetes mellitus | None or diet controlled /uncomplicated/end-organ damage | +1 (uncomplicated), +2 (end-organ damage) |
| Hemiplegia | Yes/no | +2 |
| CKD | Yes/no | +2 |
| Solid tumor | None/localized/metastatic | +2 (local), +6 (metastatic) |
| Leukemia | Yes/no | +2 |
| Lymphoma | Yes/no | +2 |
| AIDS | Yes/no | +6 |
CHF: Congestive heart failure; PVD: Peripheral vascular disease; CVA: Cerebrovascular accident; TIA: Transient ischemic attack; COPD: Chronic obstructive pulmonary disorder; CKD: Chronic kidney disease; AIDS: Acquired immunodeficiency syndrome.
Figure 3Applying and interpreting the clinical frailty score. Citation: Rockwood K, Song X, MacKnight C, Bergman H, Hogan DB, McDowell I, Mitnitski A. A global clinical measure of fitness and frailty in elderly people. CMAJ 2005; 173: 489-495. Copyright © CMA Impact Inc.
Figure 4Steps in the evaluation of decisional capacity. 1Include patient in process.
Colonoscopy-associated risks in older adults
|
|
|
|
| Perforation | Bleed, infection, necrotic bowel | Endoscopic technique (carbon dioxide insufflation, use of pediatric endoscopic equipment, careful navigation of diverticular disease), adequate bowel preparation |
| Bleeding | Post-polypectomy bleed | Hemoclip placement for bleeding prevention when appropriate, diluted epinephrine injection, use of detachable snare, thermal coagulation |
| Cardiovascular event | Arrythmia | Medication review, screen for high-risk medications, confirm dosing appropriate for renal function; adjustment of anesthesia |
| Anticoagulation therapy interruption | Risk of thrombosis, MI, CVA | Liaise with prescribing physician; avoid colonoscopy during high-risk period; avoid interruption if possible |
| Delirium | Cognitive impairment | Risk assessment; optimize medication list, avoid holding medications with withdrawal potential on morning of procedure |
| Medication interaction | Polypharmacy increases sensitivity to anesthesia | Medication review; adjustment of anesthesia |
| Dehydration | Electrolyte disturbances | Appropriate counseling prior to colonoscopy prep; caretaker supervision to ensure patient safety during prep |
MI: Myocardial infarction; CVA: Cerebrovascular accident.